Pfizer bets $2B on a new oral weight-loss therapy to rival injectables

Pfizer is pushing into the competitive weight-loss drug market with a major licensing deal. The company has secured global rights to an experimental oral therapy from Fosun Pharma. This move aims to challenge rivals already dominating the sector with blockbuster therapies.

The agreement centres on YP05002, a small-molecule pill designed to tackle obesity, Type 2 diabetes, and liver disease linked to metabolism. Pfizer's investment could exceed $2 billion if the therapy meets key development and sales targets.

The deal gives Pfizer control over YP05002, an early-stage therapy currently in Phase One trials in Australia. Developed by Yao Pharma—a subsidiary of Shanghai Fosun Pharmaceutical—it works as a GLP-1 receptor agonist. This class of therapies regulates insulin and glucagon, slows digestion, and reduces appetite.

Pfizer will pay $150 million upfront, with another $350 million possible as the therapy progresses through clinical and commercial milestones. If sales hit certain targets, Fosun could earn up to $1.59 billion more, bringing the total deal value to around $2.09 billion. However, Pfizer has included an opt-out clause if trials fail to deliver expected results.

The weight-loss market is booming, driven by demand for GLP-1 therapies like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. Both have generated billions in revenue, leaving Pfizer eager to close the gap. YP05002's oral formulation could offer a key advantage over injectable alternatives, provided it proves safe and effective in later trials.

The acquisition marks Pfizer's latest effort to compete in obesity and diabetes treatment. Success in trials would position YP05002 as a potential rival to established therapies. For now, the therapy's progress remains tied to ongoing research and regulatory approvals.